Turbine

AI-biotech company virtualizing biological experiments to accelerate oncology drug discovery.

Cover Block

Publicly reported


Name	Turbine
Tagline	AI-biotech company virtualizing biological experiments to accelerate oncology drug discovery. [Turbine website, August 2026]
Headquarters	Budapest, Hungary
Founded	2015
Stage	Series B
Business Model	B2B
Industry	Deeptech
Technology	AI / Machine Learning
Growth Profile	Venture Scale
Founding Team	Co-Founders (4)
Funding Label	Series A (total disclosed ~$27,500,000)
Total Disclosed Funding	$52.5M (estimated) [Business Wire, June 2023] [PRNewswire, February 2026]

Summary and Signal

Publicly reported Turbine is an AI-biotech company applying computational simulation to oncology drug discovery, a wedge that merits investor attention for its focus on a high-value problem and its validation by pharmaceutical partners. The company, founded in Budapest in 2015, aims to overcome the persistent failure rates and high costs of cancer research by virtualizing biological experiments with interpretable machine learning [Business Wire, June 2023]. Its core platform builds a computational model of the human cell, which it uses to simulate hundreds of millions of experiments, generating data science insights to identify novel protein targets and precision biomarkers [Cambridge Independent] [Turbine website, August 2026].

The founding team combines serial entrepreneurship with deep scientific expertise. CEO Szabolcs Nagy co-founded the company after a cybersecurity startup was acquired, while CTO Kristóf Szalay and CSO Daniel Veres provide the molecular biology and medical research foundation [Center for Data Innovation, May 2018] [Turbine website, August 2026]. This blend has supported the company's growth to 85 employees and secured a Series A round of €25.5 million in 2023, with investors including MassMutual Ventures and the MSD Global Health Innovation Fund [Business Wire, June 2023] [LinkedIn].

Turbine operates a B2B business model, deploying its virtual assays as a service across discovery programs for partners like Bayer, AstraZeneca, and Merck [PRNewswire, October 2026]. The critical watchpoint over the next 12-18 months is the translation of these research partnerships into recurring commercial contracts and the demonstration of platform-driven pipeline acceleration that can justify further scaling.

Well sourced -- Confirmed by company announcements, founder interviews, and partner disclosures.

Taxonomy Snapshot

Axis	Classification
Stage	Series B
Business Model	B2B
Industry / Vertical	Deeptech
Technology Type	AI / Machine Learning
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Series A (total disclosed ~$27,500,000)

Company Overview

Publicly reported The company's origin story is one of serial entrepreneurship converging with deep scientific expertise. Szabolcs Nagy, a founder with a background in cybersecurity, established Turbine in 2015 alongside Kristóf Szalay, Daniel Veres, and Ivan Fekete, aiming to apply computational power to the slow, costly process of biological experimentation [Center for Data Innovation, May 2018] [Business Wire, June 2023]. The founding team combined Nagy's commercial and technical background with the medical and research credentials of Veres and Fekete, and Szalay's focus on the underlying technology, creating a blend of business and science that is characteristic of the AI-biotech sector.

Headquartered in Budapest, Hungary, Turbine has since expanded its operational footprint to include offices in London and Cambridge, UK [Turbine website, August 2026]. The company's growth has been marked by two primary capital milestones. In June 2023, Turbine announced it had upsized its Series A round to €25.5 million (approximately $27.5 million), a round that included MassMutual Ventures [Business Wire, June 2023]. This was followed in February 2026 by a $25 million Series B round led by Interactive Venture Partners [PRNewswire, February 2026]. The company has grown to an estimated 85 employees, according to a LinkedIn profile [LinkedIn, István Taisz].

A key operational milestone is the reported deployment of its virtual assay platform across more than 30 discovery programs with pharmaceutical partners, a list that includes Bayer, AstraZeneca, and Merck [LinkedIn, Riccardo Guitart] [PRNewswire, October 2026]. This progression from founding and initial funding to securing validation through large-scale industry partnerships outlines a path typical for a venture-scale biotech platform.

Well sourced -- Core facts (founding date, headquarters, funding rounds, key partnerships) are confirmed by multiple independent public sources including Business Wire, PRNewswire, and the company's website.

The Product and the Stack

Public record plus analysis The core proposition is a computational platform designed to simulate human cellular biology, specifically to understand cancer mechanisms and accelerate the search for new oncology drugs. The company describes its work as "virtualizing biological experiments with AI" to identify novel protein targets and precision biomarkers [Turbine website, August 2026]. This is positioned not as a general-purpose AI model but as a specialized system combining molecular biology with interpretable machine learning to overcome limitations in identifying treatments with true patient benefit [Business Wire, June 2023].

The technology is anchored by a proprietary computational model of the human cell, which the company states can be used to simulate hundreds of millions of experiments in silico [Cambridge Independent]. This simulation engine, which the company calls its Simulated Cell platform, is the basis for generating virtual assays. These assays have reportedly been deployed across more than 30 discovery programs with pharmaceutical partners, including Bayer, AstraZeneca, and Merck [PRNewswire, October 2026]. The platform's output is data science insights aimed at target identification and treatment validation [CB Insights].

Interpretability focus. A key differentiator cited is the use of interpretable machine learning, which suggests an emphasis on providing biologically plausible mechanisms for its predictions rather than operating as a black box [Business Wire, June 2023].
Commercial deployment. The primary commercial surface appears to be collaborative research programs with large pharmaceutical companies, where Turbine's platform is applied to specific oncology discovery challenges [LinkedIn, Riccardo Guitart].
Team composition (inferred). Public team profiles and roles, including a VP of Product Innovation & Strategy and a Head of Business Development, indicate a product structure oriented around partnering and integrating computational insights into traditional R&D workflows [LinkedIn, Tamás Miklós Török] [LinkedIn, Ling Chow].

Well sourced -- Core product claims are confirmed by company announcements and third-party coverage. Partnership counts are cited in a recent press release.

The Market They Are Entering

Publicly reported The oncology drug discovery market is structurally attractive not because of its sheer size, but because of the persistent and costly inefficiencies that define it, creating a clear opening for computational approaches.

Quantifying the total addressable market for AI-driven discovery tools is challenging, as it sits at the intersection of several large, overlapping sectors. The global oncology drugs market itself is projected to reach $300 billion by 2027 [Evaluate Pharma, 2023], a figure that illustrates the ultimate commercial prize for successful therapies. More directly analogous to Turbine's proposed wedge is the market for AI in drug discovery, which some analysts estimate could grow to $7 billion by 2028 [Grand View Research, 2024]. These figures, while broad, establish the significant economic stakes and the expanding budget allocated to technological solutions aimed at improving R&D productivity.

Demand is driven by a convergence of tailwinds. The cost of bringing a new oncology drug to market remains staggeringly high, often cited at over $2 billion and taking more than a decade [Tufts Center for the Study of Drug Development]. This economic pressure is compounded by high clinical failure rates, particularly in oncology where tumor heterogeneity and complex biology lead to late-stage trial disappointments. Concurrently, the explosion of multi-omics data (genomics, proteomics, transcriptomics) has created a wealth of biological information that is too vast and complex for traditional hypothesis-driven research to fully exploit. These drivers create a powerful incentive for pharmaceutical companies to adopt in silico tools that can prioritize experiments, generate novel biological hypotheses, and de-risk programs earlier in the pipeline.

Key adjacent and substitute markets include broader preclinical research tools and contract research organization (CRO) services. Companies offering high-throughput screening, genomic sequencing services, or traditional biochemical assay development represent both potential partners and indirect competitors for R&D budget. The primary substitute, however, remains the status quo of wet-lab experimentation. The regulatory environment is a double-edged force. While agencies like the FDA and EMA are increasingly open to computational modeling and simulation as part of regulatory submissions, any tool claiming to influence clinical decisions or biomarker identification must ultimately demonstrate rigorous validation and alignment with evolving guidelines for clinical trial design and companion diagnostics.

Oncology Drug Market (2027) | 300 | $B
AI in Drug Discovery Market (2028) | 7 | $B

The chart underscores the core market dynamic: the immense value of the end goal (oncology therapies) far outweighs the current spend on the enabling tools (AI), suggesting significant room for expansion if those tools can demonstrably improve success rates.

One source, partially checked -- Market sizing figures are from third-party analyst reports, but specific TAM/SAM/SOM for virtualized oncology experiments is not publicly defined.

The Competitive Field

Public record plus analysis Turbine's competitive position is defined by its focus on simulating cellular biology for oncology, a wedge that separates it from both general-purpose AI platforms and traditional contract research organizations.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Turbine	AI-driven simulation of human cell biology for oncology drug discovery.	Series B (2026), ~$52.5M total disclosed.	Proprietary, interpretable cell model validated with major pharma partners.	[Business Wire, June 2023], [PRNewswire, February 2026]

The table highlights a fragmented competitive map where differentiation hinges on the layer of intervention. Turbine operates in the computational simulation layer, aiming to replace early-stage wet-lab experiments with in silico models. This places it against a set of adjacent but distinct challengers. Numerion Labs, for instance, appears focused on the chemistry end of discovery, predicting molecular interactions rather than modeling full cellular pathways. Arctoris competes not by replacing experiments but by automating them, offering standardized physical data generation. The incumbent substitutes are the internal discovery teams at large pharmaceutical companies and established contract research organizations (CROs), which rely on traditional high-throughput screening. Turbine's proposition is to reduce the cost and time of this initial screening funnel.

Where Turbine has a defensible edge today is in its proprietary dataset and model interpretability, cultivated through nearly a decade of focused development and specific pharma partnerships. The company's claim of deploying virtual assays across 30+ discovery programs with partners like Bayer, AstraZeneca, and Merck [LinkedIn, Riccardo Guitart] suggests it has secured early, valuable feedback loops. This partner validation is a critical form of distribution in biotech, where sales cycles are long and credibility is paramount. The edge is durable if the company continues to integrate partner data to refine its models, creating a compounding data advantage. However, it is perishable if a competitor with greater computational resources or a more attractive partnership model replicates the approach and signs similar validation deals.

The company is most exposed in two areas. First, it lacks the physical lab infrastructure of an automated platform like Arctoris, which could be seen as a more conservative, de-risked entry point for risk-averse biotechs. Second, its deep specialization in oncology, while a clear wedge, may limit its total addressable market compared to platforms targeting broader therapeutic areas. A competitor with a generalizable cell model for immunology or neurology could capture adjacent markets that Turbine's current focus does not address.

The most plausible 18-month competitive scenario hinges on partnership expansion and model validation. If Turbine successfully converts its current pharma engagements into multi-program, multi-year licensing deals, it would solidify its position as a preferred simulation partner, making it difficult for newer entrants to catch up. In this scenario, a winner would be Turbine, as its first-mover advantage in specific cancer pathways becomes entrenched. A loser would be a smaller, undifferentiated computational biology startup that fails to secure similar tier-1 pharma validation, struggling to demonstrate superior predictive power against Turbine's growing corpus of partner data.

One source, partially checked -- Competitor details are limited; subject funding and positioning are confirmed by multiple public sources.

Opportunity

Publicly reported The core opportunity for Turbine is to become the primary computational simulation layer for oncology drug discovery, a role that could compress multi-year, billion-dollar R&D cycles into a software-driven process.

The headline opportunity is the establishment of a category-defining platform for in silico oncology R&D. Rather than being another AI tool for target identification, Turbine's stated aim is to build a computational model of the human cell capable of simulating hundreds of millions of experiments [Cambridge Independent]. This positions the company to become the default simulation environment for major pharmaceutical companies exploring cancer treatments, a role analogous to a specialized, biology-native counterpart to engineering simulation software like ANSYS. The reachability of this outcome is supported by the company's reported deployment of its virtual assays across more than 30 discovery programs with partners that include Bayer, AstraZeneca, and Merck [PRNewswire, October 2026]. These early engagements with top-tier pharma provide a critical beachhead for platform validation and adoption.

Multiple concrete paths exist for Turbine to scale from a promising tool to a dominant platform. The following scenarios outline plausible, evidence-backed trajectories.

Scenario	What happens	Catalyst	Why it's plausible
Platform Standardization	A major pharmaceutical partner formally adopts Turbine's simulation as a required step in its internal oncology discovery workflow.	A multi-year, enterprise-wide partnership announcement with a top-10 pharma, expanding beyond the current program-level engagements.	The company has already validated its platform through partnerships with Bayer, MSD, and AstraZeneca [PRNewswire, October 2026], demonstrating the initial fit and trust required for deeper integration.
Therapeutic Asset Spin-out	Turbine uses its platform to discover and patent a novel, high-value oncology target, then spins out or licenses the intellectual property.	Publication of a peer-reviewed study validating a novel target identified primarily through Turbine's simulations.	The company's core technology is designed to identify novel protein targets and precision biomarkers [The Org], moving beyond service provision into direct asset creation.

Compounding for Turbine would manifest as a data and validation flywheel. Each new partnership or discovery program generates proprietary biological data and feedback, which is used to refine and expand the underlying cell model. A more accurate and comprehensive model, in turn, increases the predictive value for existing partners and attracts new ones. This creates a data moat that is difficult for new entrants to replicate without similar scale of pharmaceutical collaboration. Evidence that this cycle is beginning includes the growth from an undisclosed number of programs to "nearly 30" research programs in partnership with named industry leaders over a reported timeframe [PRNewswire, October 2026].

The size of the win, should the Platform Standardization scenario play out, can be framed by looking at the value placed on companies that successfully digitize core R&D functions. While no direct public comparable exists, the market capitalization of Recursion Pharmaceuticals (NASDAQ: RXRX), which applies automated experimentation and AI to drug discovery, provides a reference point. Recursion's enterprise value has fluctuated between $2 billion and $3 billion in recent years, reflecting the market's valuation of a technology-enabled discovery platform with a broad pipeline [public financials, 2025]. For Turbine, a focused leadership position in oncology simulation,a therapeutic area representing over 25% of the global pharmaceutical R&D spend,could support a valuation in a similar range if it achieves platform status (scenario, not a forecast).

One source, partially checked -- Core platform claims and partnership counts are cited from company announcements and executive profiles; the valuation comparable is a public market reference. The specific growth scenarios are extrapolations from the cited evidence of early traction.

Sources